The UK Medical Cannabis Market Boom (2026)
60,000+ patients, 29 teleclinics, 104% growth — the inside story of Britain's fastest-growing healthcare sector.
Since the law changed in November 2018 to allow specialist prescribing of cannabis-based medicines, the UK medical cannabis market has grown from a handful of pioneering patients into a sector valued at £230 million. By mid-2026, an estimated 60,000 to 75,000 active patients had received 659,293 prescriptions through 29 licensed teleclinics — a year-on-year growth rate of 104 percent. [Plantz/Cannavec.ai, May 2026, via Cannabis Industry Council]
The scale of expansion is staggering. The 659,293 privately dispensed cannabis items in 2024/25 represent more than double the 282,920 dispensed in 2023. The number of clinic registrations has doubled, and major private healthcare providers are entering the space with corporate backing. Industry analysts at Prohibition Partners forecast that the UK market could exceed £500 million within three years, provided regulatory bottlenecks are addressed. [Prohibition Partners, Global Medical Cannabis Market Review (2026)]
Yet for all this growth, the market remains a study in contrast. The vast majority of patients access cannabis privately, paying £150 to £350 per month for consultations and repeat prescriptions. NHS prescribing remains vanishingly rare — fewer than five patients have received a prescription through the health service since 2018. Of roughly 100,000 GMC-registered specialists legally permitted to prescribe, fewer than 180 (less than 1%) are actively doing so. The Cannabis Industry Council has repeatedly called for integrated NHS pathways, arguing that a two-tier system undermines both equity and clinical oversight. [Cannabis Health News (2026)]
The NHS Business Services Authority data tells a stark story. At the current trajectory, fewer than 1 percent of patients who could benefit from medical cannabis are receiving it through the healthcare system — what clinicians call the "1 percent prescribing problem." Because UK universities have excluded cannabis from standard medical training curricula, a tiny cohort of roughly 180 specialist consultants handles the medical intake for the entire nationwide patient base. Chronic pain (arthritis, fibromyalgia, back pain) accounts for approximately 70 percent of the market. [NHS Business Services Authority (2023–2025)]
The patient demographic defies easy generalisation. While early adopters tended to be working-age adults with chronic pain, anxiety, or insomnia, the patient pool has broadened significantly. The average patient age has risen to 42, and female patients now account for a growing share of new registrations. Veterans with PTSD represent a substantial cohort, as do older adults seeking alternatives to opioids and benzodiazepines. Approximately 95,000 individuals have received at least one prescription since 2018, with the active patient base sitting at 60,000 to 75,000. Industry reports indicate month-on-month expansion of roughly 10 percent. [Plantz/Cannavec.ai (May 2026)]
The clinic landscape has also matured into what analysts call the "teleclinic arms race." The early market was dominated by a handful of pioneers — Curaleaf Clinic (formerly Sapphire), Mamedica, and the Cannabis Access Clinics. Today, 29 licensed teleclinics compete fiercely across three fronts. First, price deflation: clinics have moved from expensive recurring consultation fees toward flat-rate corporate subscription models, with access schemes for veterans and low-income individuals. Second, frictionless tech stacks: bespoke patient apps allow secure upload of medical records, rapid eligibility screening, instant video consultations, and pharmacy tracking. Third, in-house supply chains: clinics are merging with pharmacies and licensed importers to guarantee product consistency and cut delivery times. Price competition has driven consultation fees down by roughly 30 percent since 2023, and major market leaders report year-on-year patient registry growth exceeding 100 percent. [Prohibition Partners (2026)]
The core bottleneck is that the National Institute for Health and Care Excellence (NICE) requires large-scale, UK-specific randomised controlled trials before approving widespread NHS funding — trials that remain unfunded and unconducted. This regulatory requirement means over 1.4 million ordinary British patients are priced out of legal access and forced to turn to the illicit black market for chronic pain and mental health conditions, while the UK simultaneously functions as one of the world's largest exporters of pharmaceutical-grade medical cannabis. What comes next depends largely on the regulatory environment. The Home Office has signalled no intention to expand NHS access, and successive independent reviews of the 2018 legislation have produced recommendations that patient groups describe as inadequate. If current telemedicine onboarding trajectories hold, the UK patient base is forecast to exceed 190,000 active individuals within three years, cementing medical cannabis as a permanent, highly commercialised branch of the UK healthcare landscape. The UK is now the second-largest medical cannabis market in Europe, behind Germany (nearly $1 billion). [Prohibition Partners, Global Medical Cannabis Market Review (2026)]
For a deeper look at the history and regulatory framework, read our full data on UK medical cannabis.
Key sources: [Plantz/Cannavec.ai (May 2026)] | [Cannabis Industry Council] | [Prohibition Partners] | [NHS Business Services Authority] | [Cannabis Health News]